FDA Issues Recall On Clinical Specialties Products Due To Contamination Risks

by | March 22nd, 2013

March 22, 2013

The U.S. Food and Drug Administration (FDA) has partnered with drug manufacturer, Clinical Specialties, in voluntarily recalling doses of several medications that were packaged by the company and are potentially contaminated.

On Monday, the agency issued a press release that announced the recall of more than 40 lots of the drug Avastin® that had been repackaged by the company. Avastin® is a drug that was approved by the FDA as a cancer treatment, but is also used as an off-label treatment for macular degeneration.

The drug is administered through a direct injection into the eye, but numerous reports have surfaced of individuals suffering from a Drug Injury, such as being blinded and developing internal eye infections, as a result.

Then, on Wednesday, the FDA announced a recall on all medications that had been repackaged by the company due to contamination risks.

The agency has informed anyone in possession of the affected medications to halt their use immediately and to contact the distributor for further information on disposal and replacement products.

Nurenberg, Paris, Heller & McCarthy has a team of Ohio Personal Injury Lawyers who have been recognized for their success in assisting those who have been harmed by a medication that was prescribed and administered by a doctor. That is why the firm urges anyone who has sustained such an injury to contact them immediately to discuss what legal options they may be entitled to.